MCS＋血细胞分离机在治疗性红细胞采集术中的应用

目的探讨MCS＋血细胞分离机应用于治疗性红细胞采集（TE）时的操作要点和临床观察指标。方法采用治疗性自体红细胞采集（TAE）程序，选择随机等量补充补偿液，不加添加剂模式。比较采集前后的红细胞（RBC）、红细胞比积（HCT）、血红蛋白（HGB）、B超等结果，观察治疗效果；分析比较机器显示的预计采后HCT值与实际采后的外周血HCT的差别。结果6例病人采集后外周血血常规（血Rt）示RBC、HCT、HGB均明显下降，与采集前比较差异有统计学意义（P〈0．01），原有脾肿大的患者B超均明显缩小；机器显示的预计采后HCT均比实际采后外周血HCT低，差异有统计学意义（P〈0．01）。结论应用MCS＋血细胞分离机进行他是安全有效的。

Erythropheresis with MCS＋ Blood Cell Separator

Objective To evaluate the application of MCS＋ Blood Cell （BC） separator for therapeutic erythropheresis （TE）. Method Therapeutic Autologous Erythropheresis （TAE） program was used, and the mode of operation was set to ＂Random equal volume liquid replacement＂ and ＂No additive＂. The therapeutic effect was evaluated by comparing the level of red blood cell（RBC）, hematocrit（HCT）, hemoglobin（HGB） and B-ultrasound before and after erythropheresis. Difference between the predictive value of HCT displayed in the machine and the actual value of HCT after erythropheresis was analyzed. Result The values of RBC,HCT and HGB after erythropheresis were significantly decrease （P〈0.01）. Reduced splenomegaly was also observed after the treatment. The predictive value of HCT was significantly lower than the actual value of HCT after erythropheresis （P〈0.01）. Conclusion MCS＋ BC separator is safe for therapeutic erythropheresis.